Sign In
Buy CELU
$1.06
-0.0100 (-0.93%)
At Close: Jun 02, 2026
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
08:00am, Monday, 24'th Feb 2025
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
08:00am, Tuesday, 10'th Dec 2024
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it has
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
08:00am, Friday, 06'th Dec 2024
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it file
Celularity Inc. Announces Receipt of Nasdaq Notification
05:00pm, Wednesday, 27'th Nov 2024
FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic
Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
08:30am, Wednesday, 20'th Nov 2024
FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that its strategic partner, Genti
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
08:30am, Monday, 18'th Nov 2024
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifica
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
08:30am, Wednesday, 23'rd Oct 2024
Celularity common stock and warrants will continue to trade on The Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively Celularity common stock and warrants will continue t
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
06:00pm, Friday, 18'th Oct 2024
FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologie
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
05:15pm, Wednesday, 16'th Oct 2024
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commer
Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference
04:05pm, Thursday, 05'th Sep 2024
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell the
Celularity Appoints Richard J. Berman to its Board of Directors
04:45pm, Wednesday, 28'th Aug 2024
Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value Seasoned Public Company Director and Finance Veteran Bring
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
05:00pm, Friday, 23'rd Aug 2024
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing placental-derived allogeneic cell t
FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a regenerative and cellular medicine company developing placental-derived allogeneic cell therap
FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell thera
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
05:15pm, Friday, 24'th May 2024
FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and a
